Esophagogastric Adenocarcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) | HER2-positive | Esophagogastric Adenocarcinoma | Capecitabine, Cisplatin, Trastuzumab | |
| EMA (1) | HER2-positive | Esophagogastric Adenocarcinoma | Cisplatin, Fluorouracil, Trastuzumab | |
| EMA (1) | ERBB2 amplification | Esophagogastric Adenocarcinoma | Capecitabine, Cisplatin, Trastuzumab | |
| EMA (1) | ERBB2 amplification | Esophagogastric Adenocarcinoma | Cisplatin, Fluorouracil, Trastuzumab | |
| EMA (1) | MSI-H | Esophagogastric Adenocarcinoma | Pembrolizumab | |
| EMA (1) | dMMR | Esophagogastric Adenocarcinoma | Pembrolizumab | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophagogastric Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophagogastric Adenocarcinoma | Nivolumab, Oxaliplatin |